Detail akcie Harvard Biosci online

Business Summary: Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Harvard Bioscience, Inc. revenues decreased 1% to $112.3M. Net loss decreased 64% to $3.4M. Revenues reflect Instruments, equipment, software and accessories segment decrease of 2% to $105.7M, Rest of The World segment decrease of 22% to $12.8M, United States segment decrease of 3% to $48.2M. Lower net loss reflects Restructuring Charges & Provisions decrease of 78% to $320K (expense), Selling/General/Admin.